World Federation of Hemophilia/LinkedIn
Oct 30, 2025, 06:57
For People on Emicizumab, the Use of a aPCC Raises Critical Clinical Questions
World Federation of Hemophilia shared a post on LinkedIn:
“For people on emicizumab, the use of activated prothrombin complex concentrate (aPCC) raises critical clinical questions. A new article bridges evidence with real-world practice to guide safer, smarter care decisions.”
Title: Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice
Authors: Robert F. Sidonio, Jr., Guy Young, Carmen Escuriola Ettingshausen, Johnny Mahlangu, Margareth C. Ozelo, Alok Srivastava, Jerzy Windyga, Hye–Youn Lee, Aurelia Lelli, Steven W. Pipe
Read full article here.
Stay informed with Hemostasis Today.
activated prothrombin complex concentrate (aPCC)
Alok Srivastava
Aurelia Lelli
Carmen Escuriola Ettingshausen
Emicizumab
Guy Young
Health
Hematology
Hemostasis
Hemostasis Today
Hye–Youn Lee
Jerzy Windyga
Johnny Mahlangu
Jr.
Margareth C. Ozelo
Medicine
Robert F. Sidonio
rpth
Steven W. Pipe
World Federation of Hemophilia
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy